H.R.2672 - Preserving Access to Orphan Drugs Act of 2011112th Congress (2011-2012)
|Sponsor:||Rep. Gerlach, Jim [R-PA-6] (Introduced 07/27/2011)|
|Committees:||House - Energy and Commerce; Ways and Means|
|Latest Action:||House - 08/01/2011 Referred to the Subcommittee on Health. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Summary: H.R.2672 — 112th Congress (2011-2012)All Information (Except Text)
Introduced in House (07/27/2011)
Preserving Access to Orphan Drugs Act of 2011 - Amends the Patient Protection and Affordable Care Act (PPACA) to exclude any drug or biological product which is approved or licensed by the Food and Drug Administration (FDA) for marketing solely for one or more rare diseases or conditions from the annual fee on manufacturers or importers with branded prescription drug sales exceeding $5 million.
Makes this Act effective as if included in PPACA.